InvestorsHub Logo
Followers 0
Posts 468
Boards Moderated 0
Alias Born 10/07/2012

Re: md1225 post# 126804

Sunday, 06/09/2013 1:10:04 PM

Sunday, June 09, 2013 1:10:04 PM

Post# of 345969
OK, so the p3 Bevazicumab results were a lot worse (12.3) than the p2 (16.5) you referred to in your previous post. I believe, generally, the p3 trials often lag p2 trials in efficacy. So, to convince the street and BP we need to beat the p2 Avastin results which calls for about 18+ months for MOS.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News